Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitapivat in adult patients with erythrocyte membranopathies
2023-503271-24-01Phase 2Authorised
- Sponsor
- EuroBloodNet Association
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of mitapivat in erythrocyte membrane disorders and Congenital Dyserythropoietic Anemia Type 2, sponsored by EuroBloodNet Association. Primary endpoints: Overall safety profile of mitapivat, Incidence of treatment-emergent adverse events and 5 more. Planned start Dec 2023; status: authorised.
02
Drugs
mitapivat
03
Conditions
erythrocyte membrane disordersCongenital Dyserythropoietic Anemia Type 2
Beyond the preview
Go deeper on 2023-503271-24-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503271-24-01.